DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. - Wikidata - awgldk - TriplyDB

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

http://www.wikidata.org/entity/Q37714183

about

Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor Genetics and cardiovascular disease: a policy statement from the American Heart Association.Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients?Evaluating the role of Cardiac Genetics Nurses in inherited cardiac conditions services using a Maturity Matrix.Molecular genetics made simple.The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease.Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history Genetic advances in sarcomeric cardiomyopathies: state of the art.Why is genetic screening for autosomal dominant disorders underused in families? The case of hereditary hemorrhagic telangiectasia.The cost-effectiveness of returning incidental findings from next-generation genomic sequencing.Genetics of inherited cardiomyopathy.Genetics and genotype-phenotype correlations in Finnish patients with dilated cardiomyopathy Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review A Case for Inclusion of Genetic Counselors in Cardiac Care A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers.Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology.Who Pays? Coverage Challenges for Cardiovascular Genetic Testing in U.S. Patients Pre-symptomatic genetic testing for inherited cardiac conditions: a qualitative exploration of psychosocial and ethical implications.Clinical utility gene card for: arrhythmogenic right ventricular cardiomyopathy (ARVC).Recent advances in the epidemiology, pathogenesis and prognosis of acute heart failure and cardiomyopathy in Africa.Genetic test for dilated and hypertrophic cardiomyopathies: useful or less than useful for patients?Almanac 2014: cardiomyopathies.Hypertrophic cardiomyopathy: how do mutations lead to disease?Assessing the value of cardiac biomarkers: going beyond diagnostic accuracy?Differences in Presentation and Outcomes Between Children With Familial Dilated Cardiomyopathy and Children With Idiopathic Dilated Cardiomyopathy: A Report From the Pediatric Cardiomyopathy Registry Study Group.The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the Clinical utility gene card for: hypertrophic cardiomyopathy (type 1-14)Evolving Approaches to Genetic Evaluation of Specific Cardiomyopathies.Contextualizing Genetics for Regional Heart Failure Care Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity.Clinical utility gene card for: dilated cardiomyopathy (CMD).NGS identifies TAZ mutation in a family with X-linked dilated cardiomyopathy Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy.Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results.Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study.Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions Recent Developments in the Genetics of Cardiomyopathies

P2860

Q26996693-D383CFE6-DAEC-4987-88F3-EE578A167218 Q30418104-BCE9041C-1724-4358-9E70-5319AF5F8056 Q30430827-9B7A21C7-7509-4C07-B1EC-BD69172A7F3A Q30847127-EF7923E7-B691-495D-96E6-6109A350C9BF Q34553729-C891684E-E56E-4632-87A2-6FC2F69EE128 Q34579841-8E7646B7-6CF6-4AC2-A1B4-951E63CCB3F8 Q34772983-5B81A642-3094-491C-A863-4791037B635B Q35145962-DDF92EEA-1CF3-4501-8B55-BF828D51715B Q35194662-A0002C0F-A405-4173-BC39-CD5D4461A0A9 Q35602902-6ADCECC3-DC9F-4ED9-89B7-DFFC90230DDE Q35721684-D9649A80-CF41-4BCA-A4C4-2F8DEA45B3E2 Q36032075-DB2A10F4-F273-4089-93C1-D06C307007A2 Q36304418-E3BDDF23-0400-4869-81EF-44C8A274623A Q36470860-16FE63F9-26D4-45A8-8525-0A7FA18F966C Q36541715-D609EC2C-886E-419A-9E33-C6891B4D46F7 Q36587026-71D3CE32-7328-4361-B5D0-1C789F812F08 Q36948619-A1C0C194-EC05-4158-A1EA-DA2F99D176A0 Q37397650-AEEC6D77-E56E-4131-8305-7C3B071A23ED Q37493092-5A457122-97BD-49B4-9221-B5DA1C4DE254 Q38107367-657652A4-EA97-4DFA-AAD2-004C757633EE Q38125689-3485E01A-BFA8-4905-AD0B-8034E71E7BD1 Q38193960-37861FED-D7EA-4FAD-AE47-4E50CE1C2E55 Q38203157-A44F32A1-EA30-4C5A-BB19-6B0989C57240 Q38224400-1EE524FE-A02B-4AA6-AD36-EE9B788EBAE1 Q38380886-AC028121-6FFD-488D-BA2C-574579CEF07C Q38407538-A97D1934-0069-4B26-8BBD-1D86229943DB Q38413180-2C754ABE-A6CA-45D0-9C8E-FABA1E13B9BA Q38608486-9B9EA146-6116-444A-AAE6-15C3A22A255C Q38859880-AA9B7BF6-C314-426D-BDF0-2E4D5B9A43C0 Q41543943-AEDA780C-F34E-4549-9DB5-74AC7F976946 Q41791204-2DF15700-C3A5-40F7-B5A4-790894B807D6 Q42176683-9B98296F-C0D1-478A-A285-085D30E47DF8 Q43513639-3EC82B8A-2C87-4849-B15C-B10FCEC03DC4 Q45999934-EB2EDB3A-5CB7-42D1-96B0-91C431516BAF Q51210207-EFA77631-4A7D-4827-8A11-F8AAFBE3E7AE Q57697360-38E08BA4-F062-4F69-B21D-9ADD2BA0D4CF Q58616245-2D8D2119-3216-4D47-AF70-A4330FA15FA5

P2860

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

http://www.wikidata.org/entity/Q37714183

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

@en

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

@nl

type

label

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

@en

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

@nl

prefLabel

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

@en

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

@nl

P1433

Q37714183-0B4AB49F-3157-4EE3-9836-3D7572E2AF30

P1476

Q37714183-BFEE12D0-370C-4BEE-8416-2BE4732A8D23

P2093

Q37714183-3D5D19C8-C11D-4E96-9B6A-DB657A38A821

Q37714183-43BDC897-4BD4-4A9B-A9F7-797C8F48CA82

Q37714183-9E985F52-0BD6-4733-8B78-9B7757BF691D

Q37714183-A409298C-97B8-4E17-830E-E99AA9EFD7A5

Q37714183-D4E99C83-B0F5-404A-8512-ED91C109844C

Q37714183-E079AE4D-CB8D-435D-970E-65E705DA159C

P2860

Q37714183-1D3049FE-D84D-440B-8DD4-8A06773A6421

Q37714183-471AE7A1-9EB8-42FE-AE8D-9D05FE8F6D13

Q37714183-58E61C59-79ED-442B-B69B-224ACADF41D0

Q37714183-7FC93D69-2168-410D-9F1F-E339FD6EA29C

Q37714183-804BC08E-ED09-4E42-94D3-DA878404D565

Q37714183-8E374F44-C52B-4165-B7D5-FE5ED4242BA0

Q37714183-910FC709-920E-4D5B-98A0-C75526F87217

Q37714183-CA6BD015-75B0-4595-BE85-70AE84E70723

P304

Q37714183-7521FB3E-A703-494D-91E8-CDFE13F3B1BB

P31

Q37714183-11EE1F05-E4BB-4B82-BA01-BEB11CD38319

P356

Q37714183-9C76B589-30C4-4098-B818-90B6F913955C

P433

Q37714183-EE4486FB-7E62-46EA-B488-80D24870EA11

P478

Q37714183-B7D1B6D9-6194-4F36-9D64-851FB267C8C8

P50

Q37714183-19C120D8-43F3-48FB-BAAD-6D99277BACD9

Q37714183-3CFD04D8-6EE1-4772-9794-96C053634939

P577

Q37714183-D41A14D1-F50A-424A-B9C2-6309315CFFA5

P5875

Q37714183-1BF13DA6-BC34-49AD-9762-5A870B31E3A2

P698

Q37714183-9F824FBB-B1E5-4E6B-8CB1-5FD6ACE3F9BC

P356

P1433

European Heart Journal

P1476

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

@en

P2093

Anneke Seller

http://www.w3.org/2001/XMLSchema#string

Edward Blair

http://www.w3.org/2001/XMLSchema#string

Jenny Taylor

http://www.w3.org/2001/XMLSchema#string

José Leal

http://www.w3.org/2001/XMLSchema#string

Rosa Legood

http://www.w3.org/2001/XMLSchema#string

Sarah Wordsworth

http://www.w3.org/2001/XMLSchema#string

P2860

Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death

Sudden death in hypertrophic cardiomyopathy: identification of high risk patients.

Hypertrophic cardiomyopathy: a systematic review.

Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy

Reviews of translational medicine and genomics in cardiovascular disease: new disease taxonomy and therapeutic implications cardiomyopathies: therapeutics based on molecular phenotype.

Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles.

Epidemiology of Hypertrophic Cardiomyopathy–Related Death

ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities

P304

926-935

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHQ067

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Hugh Christian Watkins

P577

2010-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42344935

http://www.w3.org/2001/XMLSchema#string

P698

20299350

http://www.w3.org/2001/XMLSchema#string